NCT03238196View on ClinicalTrials.gov

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 18, 2017

Primary Completion Date

April 30, 2021

Study Completion Date

March 20, 2024

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Erdafitinib

4mg - 8mg

DRUG

Palbociclib

125 mg

DRUG

Fulvestrant

500 mg

Trial Locations (6)

10065

Memorial Sloan-Kettering Cancer Center, New York

15213

University of Pittsburgh Medical Center, Pittsburgh

35233

University of Alabama, Birmingham

37232

Vanderbilt-Ingram Cancer Center, Nashville

38120

Baptist Memorial Hospital MEMPHIS, Memphis

75235

University of Texas Southwestern Simmons Comprehensive Cancer Center, Dallas

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT03238196 - Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter